JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266365

Human TRAPPC2L knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TRAPPC2L KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

HSPC176, Trafficking protein particle complex 2 like

1 Images
Sanger Sequencing - Human TRAPPC2L knockout HEK-293T cell line (AB266365)
  • Sanger seq

Unknown

Sanger Sequencing - Human TRAPPC2L knockout HEK-293T cell line (AB266365)

Homozygous : 1 bp insertion in exon 2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266365-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266365-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266365 Human TRAPPC2L knockout HEK-293T cell line", "number":"AB266365-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266365-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266365 Human TRAPPC2L knockout HEK-293T cell line", "number":"AB266365-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266365-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266365-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266365 Human TRAPPC2L knockout HEK-293T cell line", "number":"AB266365-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266365-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266365 Human TRAPPC2L knockout HEK-293T cell line", "number":"AB266365-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TRAPPC2L
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TRAPPC2L also known as trafficking protein particle complex 2L is a protein approximately 52 kDa in mass. It plays a role in vesicle-mediated transport processes. TRAPPC2L is widely expressed in various tissues but shows higher expression in the adrenal gland and testis. Its mechanical function involves the regulation of intracellular protein trafficking which is important for transporting proteins to their proper destinations within cells.
Biological function summary

This protein is a component of the TRAPP complex a multi-subunit protein assembly involved in the tethering of transport vesicles before fusion with their target membranes. TRAPPC2L contributes to the function and structural integrity of this complex which is essential for maintaining cellular organization and exchanging materials between different cellular compartments. This involvement implies that TRAPPC2L plays a significant part in cellular logistics and maintenance of homeostasis.

Pathways

TRAPPC2L engages in the secretory pathway interfacing with the SNARE proteins necessary for vesicle fusion. This protein also links to the Ypt/Rab GTPases pathway which regulates vesicular transport and budding processes. Through these interactions TRAPPC2L associates with proteins like TRAPPC2 and TRAPPC3 enhancing vesicle tethering and trafficking dynamics.

TRAPPC2L shows associations with medical conditions such as congenital disorders of glycosylation and nephrotic syndrome. Deficient or dysfunctional TRAPPC2L can disrupt vesicle transport pathways leading to cellular dysfunction and disease. The pathways connected to TRAPPC2L can also involve other proteins like TRAPPC2 and TRAPPC9 which contribute to the pathology through their interconnected roles in similar transport processes.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com